Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of a monoclonal antibody called DI-B4 for low grade B cell lymphoma and chronic lymphocytic leukaemia
Coronavirus and cancer
We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.
This trial looked at a new drug called DI-B4 for low grade B cell lymphoma and chronic lymphocytic leukaemia (CLL). The people taking part had lymphoma or leukaemia that was getting worse or had come back despite having other treatment.
Cancer Research UK supported this trial.
More about this trial
- find the highest safe dose of DI-B4
- find out what happens to DI-B4 in the body
- learn more about the side effects
- see how well treatment worked
Summary of results
- 16 people joined part 1
- 12 people joined part 2
- in 3 people their lymphoma went away a little bit - we call this a partial response
- in 12 people it stayed the same - we call this stable disease
- in 6 people it had got worse
- this was more than 6 months in 6 people
- this was just under 18 months in 1 person
- the average length of time before the cancer started to grow again was 157 days
- tiredness (fatigue)
- feeling or being sick
- a reaction to the infusion
- a drop in
white blood cells
- white blood cells that help fight infection
- platelets that help the blood to clot
How to join a clinical trial
Dr Andrew Davies
Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUKD/12/003.